Acumen Pharmaceuticals

ABOS · NASDAQ

$2.02+$0.245 (+13.84%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $1.77

ABOS analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 7 analysts

Average $7.75 (+284.7% upside)

Low: $5.05
Now: $2.02
High: $10.50

Upgrades and downgrades

The latest rating actions, newest first

ABOS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
BTIG	Sep 16, 2026	Maintains	Buy	$8.00	30%
Citigroup	Sep 15, 2026	Maintains	Buy	$4.00 → $5.00	60%
BTIG	Mar 26, 2026	Maintains	Buy	$8.00	30%
BTIG	Mar 16, 2026	Maintains	Buy	$7.00 → $8.00	30%
BTIG	Jan 27, 2026	Maintains	Buy	$4.00 → $7.00	30%
B of A Securities	Nov 18, 2025	Maintains	Buy	$9.00 → $8.00	60%

The case for and against

Updated Mar 20, 2025

Bull case

Acumen Pharmaceuticals Inc. is focused on developing a novel monoclonal antibody, ACU193, aimed at addressing Alzheimer's disease by selectively targeting amyloid-beta oligomers, which positions the company at the forefront of innovative therapeutic approaches in the field. Positive trends in clinical data regarding biomarkers such as ptau181 and Abeta42/40 indicate potential for significant efficacy in driving changes in neurodegeneration, bolstering confidence in the effectiveness of anti-A-beta therapies. Moreover, the observed rapid reduction in plaque levels among symptomatic patients highlights the drug's potential to modify the disease's progression, suggesting a promising outlook for the company's future developments.

Bear case

Acumen Pharmaceuticals reported a significant net loss of $29.8 million, or $0.50 per share, for the quarter, indicating financial challenges that may impact future operations. The company faces substantial risks related to its drug candidate ACU193, including potential failure in clinical trials, regulatory approval in the US and EU, and achieving peak commercial revenue estimates due to market limitations. Additionally, concerning findings regarding the toxic effects of amyloid-beta oligomers on synapses highlight scientific uncertainties that could further jeopardize the drug’s development and overall investment prospects.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.